VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HCAHCA Healthcare, Inc.
$391.68$86.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksHCACash Flow

HCA Healthcare, Inc. (HCA) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow margins have compressed to 4.7% in 2026Q1, while management continues to prioritize aggressive capital allocation, including quarterly buybacks that have frequently exceeded $2B.

HCA Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations13B12.64B10.51B9.43B8.52B8.96B9.23B7.6B6.76B5.43B5.65B4.73B4.45B3.68B4.17B3.93B3.08B2.75B1.8B1.4B1.84B3.16B3.05B2.17B2.75B1.41B1.55B1.22B1.92B1.48B2.62B
Operating CF Margin %-16.71%14.89%14.52%14.15%15.25%17.91%14.81%14.48%12.44%13.63%11.93%12.05%10.77%12.65%12.1%10.05%9.14%6.33%5.2%7.24%12.92%12.97%9.93%13.94%7.87%9.28%7.34%10.26%7.88%13.16%
Operating CF Growth %153.4%20.18%11.48%10.67%-4.88%-2.96%21.44%12.44%24.6%-4.02%19.41%6.43%20.87%-11.86%6.15%27.49%12.3%52.87%28.72%-24.34%-41.6%3.61%40.77%-21.24%94.62%-8.66%26.49%-36.17%29.2%-43.42%16.28%
Net Income6.79B6.78B6.66B5.24B6.83B7.72B4.39B4.14B4.39B2.74B3.43B2.7B2.37B2B2.01B2.84B1.57B1.38B673M874M1.04B1.42B1.25B1.33B833M886M219M657M532M126M1.5B
Depreciation & Amortization3.59B3.52B3.31B3.08B2.97B2.85B2.72B2.6B2.28B2.13B1.97B1.9B1.82B1.75B1.68B1.47B1.42B1.43B1.42B1.43B1.39B1.37B1.25B1.11B1.01B1.05B1.03B1.09B1.25B1.24B1.16B
Stock-Based Compensation99M0360M0341M440M362M347M268M270M251M239M163M113M56M26M32M40M32M24M324M0000000000
Deferred Taxes388M022M229M571M-70M41M250M74M433M123M-160M-83M143M96M1.71B2.85B169M2.78B1.81B1.44B00000000-163M0
Other Non-Cash Items-904M1.6B269M1.34B-1.04B-1.48B443M352M-281M145M-161M378M439M89M231M842M58M2.83B261M878M591M2.64B3.13B1.86B2.54B1.08B2.03B1.16B1.58B1.92B71M
Working Capital Changes2.79B728M-106M-457M-1.15B-503M1.28B-88M33M-296M42M-323M-264M-414M107M-2.95B-2.85B-3.09B-3.37B-3.62B-2.94B-2.28B-2.58B-2.14B-1.63B-1.6B-1.74B-1.69B-1.45B-1.64B-110M
Change in Receivables-230M-94M-799M-935M-797M-962M327M-326M-423M-4.64B-3.25B-4.11B-3.65B-4.39B-3.9B-3.25B-2.79B-3.18B-3.33B00-2.65B000000000
Change in Inventory286M-154M334M-126M-59M-540M-304M-158M-242M-69M-112M-314M-232M-19M-122M-18M-287M-191M159M-241M-12M28M-46M32M-88M-39M90M-119M-39M25M-29M
Change in Payables676M666M359M604M-296M999M1.25B396M698M374M144M192M3.88B4.41B4.02B0000000000000000
Cash from Investing-5.24B-4.99B-4.93B-5.32B-3.39B-2.64B-3.39B-5.72B-3.9B-4.28B-3.24B-2.58B-2.92B-2.35B-2.06B-3B-1.04B-1.03B-1.47B-479M-1.31B-1.68B-1.69B-2.86B-1.74B-1.3B-1.09B925M970M-2.75B-2.25B
Capital Expenditures-5.07B-4.94B-4.88B-4.74B-4.39B-3.58B-2.83B-4.16B-3.57B-3.02B-2.76B-2.38B-2.18B-1.94B-1.86B-1.68B-1.32B-1.32B-1.6B-1.44B-1.86B-1.59B-1.51B-1.84B-1.72B-1.37B-1.16B-1.29B-1.25B-1.42B-1.4B
CapEx % of Revenue6.64%6.54%6.9%7.3%7.3%6.09%5.5%8.1%7.65%6.91%6.65%5.99%5.89%5.68%5.64%5.17%4.32%4.38%5.64%5.38%7.32%6.51%6.44%8.43%8.71%7.63%6.93%7.73%6.72%7.56%7.03%
Acquisitions-324M-128M62M-442M1.01B1.05B-500M-1.62B-445M-1.21B-576M-278M-715M-448M-228M-1.4B-196M-20M108M735M539M194M4M-745M11M280M-23M805M1.84B-411M-816M
Investments-------------------------------
Other Investing9M12M-120M-131M-7M-121M-58M59M60M-52M96M70M-27M45M27M85M482M-1M25M230M19M-283M-179M-279M-33M-210M91M1.41B674M-1.05B185M
Cash from Financing-7.88B-8.55B-4.58B-4.09B-5.66B-6.66B-4.68B-1.77B-3.08B-1.06B-2.51B-1.98B-1.38B-1.63B-1.78B-976M-1.95B-1.86B-258M-1.16B-240M-1.4B-1.35B650M-934M-342M-336M-2.25B-2.7B1.26B-489M
Debt Issued (Net)3.08B3.21B3.21B1.29B3.29B3.25B-3.22B567M-344M1.51B815M778M778M-692M1.72B-1.59B2.53B-1.53B-260M-1.25B17.59B-106M1.78B1.57B-466M608M922M-535M-2.66B2.38B-423M
Equity Issued (Net)-9.13B-10.07B-6.04B-3.81B-7B-8.21B-441M-1.03B-1.53B-2.05B-2.75B-2.4B-1.75B-500M01B000100M-20.91B-847M-2.88B-949M-15M-1.29B-677M-1.88B8M-1.08B0
Dividends Paid-682M-679M-690M-661M-653M-624M-153M-550M-487M000-7M-16M-3.15B-31M-4.26B000-201M-258M-199M-39M-40M-42M-44M000-54M
Share Repurchases-9.13B-10.07B-6.04B-3.81B-7B-8.21B-441M-1.03B-1.53B-2.05B-2.75B-2.4B-1.75B-500M0-1.5B0000-21.02B-1.86B-3.11B-1.11B-282M-1.51B000-1.08B0
Other Financing-1.16B-1.01B-1.05B-917M-1.29B-1.07B-866M-757M-714M-519M-572M-357M-399M-417M-356M-359M-223M-336M2M-3M3.27B-189M-41M65M-413M385M-537M164M-49M-42M-12M
Net Change in Cash-120M-893M998M27M-543M-342M1.17B119M-230M86M-95M175M152M-291M332M-38M99M-153M72M-241M298M78M14M-46M76M-229M124M-107M187M-3M-119M
Free Cash Flow7.93B7.69B5.64B4.69B4.13B5.38B6.4B3.44B3.19B2.41B2.89B2.36B2.27B1.74B2.31B2.25B1.76B1.43B197M-48M-20M1.57B1.54B328M1.03B43M392M-64M661M61M1.22B
FCF Margin %10.38%10.17%7.99%7.21%6.85%9.16%12.41%6.71%6.83%5.53%6.97%5.95%6.15%5.08%7.01%6.93%5.74%4.76%0.69%-0.18%-0.08%6.41%6.54%1.5%5.23%0.24%2.35%-0.38%3.54%0.32%6.13%
FCF Growth %60.21%36.41%20.31%13.57%-23.32%-15.87%85.74%8.03%32.23%-16.66%22.64%3.83%30.8%-24.9%2.62%28.07%23.08%625.89%510.42%-140%-101.28%2.02%368.29%-68.22%2300%-89.03%712.5%-109.68%983.61%-95%67.95%
FCF per Share34.9733.3421.5416.9614.0116.3718.529.898.976.487.315.535.043.765.034.544.024.100.56-0.14-0.053.503.180.641.970.080.71-0.101.020.091.80
FCF Conversion (FCF/Net Income)1.17x1.86x1.83x1.80x1.51x1.29x2.46x2.17x1.79x2.45x1.96x2.22x2.37x2.37x2.60x1.60x2.56x2.61x2.67x1.60x1.78x2.22x2.45x1.63x3.30x1.59x5.30x1.65x4.07x-4.86x1.74x
Interest Paid1.16B01.94B1.89B1.66B1.5B1.61B1.91B1.74B1.7B1.67B1.65B1.76B1.83B1.72B1.99B1.99B1.75B1.98B2.16B893M624M533M00000000
Taxes Paid217M01.84B1.39B1.18B2.18B1B849M872M1.21B1.25B1.19B1.06B694M618M256M517M1.15B716M421M1.09B563M394M00000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Working capital volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality and Cash Conversion

According to reported financial statements, HCA's operating cash flow to net income ratio fluctuated significantly, reaching a high of 2.77 in 2024Q3 before settling at 1.24 in 2026Q1, which suggests that reported earnings are frequently decoupled from the actual cash generated by core hospital operations.

The persistent gap between net income and operating cash flow indicates that non-cash adjustments and working capital swings play an outsized role in HCA's reported profitability. Investors should monitor whether this volatility stems from the timing of supplemental government payments or underlying challenges in converting service revenue into realized cash.

Free Cash Flow Margin Compression

As indicated by recent quarterly data, HCA's free cash flow margin has experienced notable contraction, falling from a peak of 16.3% in 2025Q3 to just 4.7% in 2026Q1, reflecting a period of diminished cash generation relative to the scale of the company's revenue base.

This downward trend in FCF margins suggests that the company's ability to self-fund operations and capital requirements is currently under pressure. The inconsistency in cash flow generation may imply that the high-acuity service model is becoming increasingly sensitive to rising operational costs and reimbursement timing.

Capital Intensity and Asset Maintenance

Based on HCA's reported figures, capital expenditure as a percentage of revenue has remained relatively stable, averaging between 5.4% and 7.6% over the last ten quarters, which suggests a consistent commitment to maintaining its extensive network of acute care facilities and medical infrastructure.

While this level of investment is necessary to support the cluster strategy, the lack of significant reduction in capital intensity during periods of margin pressure warrants further investigation. It appears management is prioritizing facility modernization to defend market share, even as cash flow generation becomes more erratic.

Working Capital Volatility and Efficiency

Data from recent filings reveals extreme volatility in working capital changes, ranging from a $2.3B inflow in 2025Q3 to a $1.7B outflow in 2025Q1, highlighting the significant impact of timing differences in collections and payables on the company's quarterly liquidity profile.

Such swings suggest that HCA's cash flow is highly susceptible to the timing of government reimbursement cycles and potential delays in commercial insurance settlements. This operational reality makes short-term cash flow forecasting difficult and may obscure the underlying efficiency of the company's revenue cycle management.

Aggressive Capital Allocation Strategy

According to historical cash flow statements, HCA has consistently prioritized share repurchases, with quarterly buybacks frequently exceeding $2B, even during periods where free cash flow generation was significantly lower, suggesting a management preference for returning capital to shareholders over maintaining a large cash buffer.

This aggressive deployment strategy appears to rely on the assumption of stable, recurring cash flows that have not materialized consistently in recent quarters. Investors should monitor whether this pace of buybacks remains sustainable if the current trend of margin compression and working capital volatility persists.

HCA — Frequently Asked Questions

Quick answers to the most common questions about buying HCA stock.

How much cash does HCA Healthcare, Inc. (HCA) generate from operations?

HCA Healthcare, Inc. (HCA) generated $12.64B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is HCA Healthcare, Inc.'s free cash flow?

HCA Healthcare, Inc. (HCA) generated $7.69B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is HCA Healthcare, Inc.'s capital expenditure (CapEx)?

HCA Healthcare, Inc. (HCA) spent $4.94B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does HCA Healthcare, Inc. distribute cash to shareholders?

In 2025, HCA Healthcare, Inc. (HCA) returned $679.0M to shareholders via cash dividends and spent $10.07B on share repurchases. This shows the company's commitment to returning capital to its equity investors.